Objective: Patients with Parkinson's disease (PD) may have sensory dysfunction, and it can be more easily demonstrated through electrophysiologic testing. We aimed to explore whether the impairment of brainstem visual and auditory passageway exists in PD patients using visual evoked potential (VEP) and brainstem auditory evoked potential (BAEP) examinations.
| INTRODUCTION
PD is a common degenerative disease of central nervous system among middle-aged populations. Its typical signs include distal resting tremor, bradykinesia, rigidity, and postural disturbances. Patients with PD may have sensory dysfunctions such as visual dysfunction, olfactory dysfunction, vestibular dysfunction, and pain. Most of these abnormalities are relatively subtle from a clinical point of view but can be more easily demonstrated through electrophysiologic or psychophysical testing.
The diagnosis of PD currently mainly depends on the identification of disease history, symptoms, and physical examination, which are difficult to be quantitative and objective. Because of the variability of PD symptoms, the severity and clinical staging of PD cannot be accurately assessed in clinical practice. The measurement of the evoked potential (EP) is a widely used noninvasive technique for studying the functional changes in neural conductive pathway of PD. Some studies demonstrated VEP or BAEP in patients with PD, but the results were inconsistent (Deng, Deng, Zhao, Yan, & Chen, 2006; Li, 2004; Venhovens, Meulstee, Bloem, & Verhagen, 2016; Vitale et al., 2012; Yylmaz et al., 2009 ). So our study explored whether the impairment of brainstem auditory and visual passageway exists in patients with PD using VEP and BAEP. It can imply the location of impairment was in the brainstem or the end organ and find its association with the clinical stage and severity of the disease. 
| PATIENTS AND METHODS

| Subjects
| Methods
All enrolled patients underwent a series of detailed history examinations. Hamilton Anxiety and Depression Scale was used to evaluate the psychological state, and the mini-mental state examination (MMSE) was used to test the intelligence. All the results of these scales were in normal range. Severity of disease was assessed by UPDRS-III, and stage of PD was assessed by H&Y classification.
All patients experienced these assessments and were between the H&Y stages 1 and 4 (mean 2.01). The ophthalmologic evaluations were performed at eye clinic and comprised a visual acuity test (Snellen table) , an Ishihara colors test, a biomicroscopy, and an intraocular pressure measurement using the Goldmann applanation tonometer. The hearing tests included standard audiometric puretone air and bone conduction testing. All patients, except two, were all on L-dopa or a dopamine agonist therapy. Patients were assessed in the "on" state before the morning dose of the drug. The daily dose of dopa therapy was calculated by addition of a daily dose of levodopa and the dopaminergic agonists transcribed as "doseequivalent dopa" (Krack et al., 1998; Lozano et al., 1995) . The mean body mass index (BMI) and years of education were also measured.
The purpose of the detection should be explained to the patients in advance.
The VEP and BAEP were demonstrated by Evoked Potential Response Unit (Keypoint 4, Dantec™, Denmark) in a dim and quiet room in Zhoushan Hospital. VEP used a black-white checkered-board pattern on a television monitor with a dimension of 5×5 cm for every check. The patterns had a contrast of 60%, and the mean luminance was 300 cd/m 2 . Contrast is defined as the difference between the maximum and minimum luminance of adjacent vertical bands over their sum. The reversal rate was 3 Hz. The observer's distance was 100 cm from the screen. The recording electrode was in the midline and 5 cm above the inion with the reference 20 cm anterior to it. Viewing was monocular, and both eyes were tested separately in each subject. N75, P100, N145 latencies, and P100 amplitude were measured, and the averaged data of left and right eye in each subject were recorded. BAEP recording electrode was placed at Cz while the reference electrode at earlobe and the ground electrode on the forehead according to international standard 10-20 system. The short sound was used to stimulate the target ear with the interval of 0.1 ms, the frequency of which was 11.1 Hz, intensity was 105 db, superposition was 2048 times while the opposite one screened noisily, and then repeated for twice or more in the same way. Both ears were tested separately in each subject. Figure 3 shows BAEP wave patterns of a healthy individual in the control group and a patient with PD. As seen in Table 3 , patients with PD showed significantly increased latencies in waves III and V compared with control subjects (p = .001, p = .010, respectively) ( Table 3) 
| RESULTS
| Quantitative analysis of participants
| Abnormality of VEP
| Abnormality of BAEP
| The correlation of VEP and BAEP with others
The P100 latency of VEP was positively correlated with the ages (r = .375, p = .014) ( Table 4 , Figure 5a ), UPDRS score (r = .629, p < .001) ( Table 4 , Figure 5b ), and H&Y classification (r = .597, p < .001) (Table 4, Figure 5c ) while it did not show any relation between P100 latency with duration of disease and dopa dose (Table 4) in patients with PD. Partial correlation analysis showed that when controlling the UPDRS and H&Y covariates, there is no correlation between P100 latency and ages. However, when controlling the age covariate, the results changed little. The III-V IPL of BAEP was only found positively correlated with UPDRS score (r = .398, p = .009) ( It is worth noted that VEP measures the integrity of the entire visual pathway. The changes in these potentials in PD may reflect the widespread nature of the biochemical disorder affecting both retina and central nervous system. P100 latency is less likely to be affected From the result of present study, the N75, P100, N145 components of VEP had more prolonged latency in patients with PD than controls, which was inconsistent with some other studies (Li, (Tsuji, Muraoka, Kuroiwa, Chen, & Gajdusek, 1981) , Prasher and Bannister (Prasher & Bannister, 1986) have reported normal BAEPs in patients with PD.
The exact etiology and pathogenesis of PD remain elusive while it is widely accepted that PD is caused by progressive loss of dopaminergic neurons in the substantia nigra. In our study, VEP and BAEP Some studies found that substitution of dopaminergic drugs was shown to reverse VEP delays in patients with PD (Barbato, Rinalduzzi, Laurenti, Ruggieri, & Accornero, 1994; Bodis-Wollner & Yahr, 1978; Onofrj, Ghilardi, Basciani, & Gambi, 1986 ) while someone observed no improvement after levodopa (Nightingale, Mitchell, & Howe, 1986) . Podoshin et al. Podoshin, Ben-David, Fradis, and Pratt (1987) and Fradis et al. Fradis et al., (1988) found no significant differences of BAEP between patients with PD under dopaminergic drugs treatments and those without treatment. Our study found no significant correlation between EP and dopa dose. It may be explained that the dopa dose had positive correlation with clinical duration as we had found. As PD developing, more dopa was used. So we were not able to reveal the real correlation between the EP and dopaminergic drugs as the duration and severity of PD were different.
| CONCLUSION
Above all, our results found that brainstem visual and auditory passageway may be impaired besides the involvements of substantia nigra and striatum in patients with PD. Both extra corticospinal tract and the sensory system are involved in patients with PD. VEP and BAEP can be effective tools for detecting the functional changes of brainstem in patients with PD and may help in prognosis and assessment the severity of the disease. Further research is needed to explore the mechanisms underlying this relationship.
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